Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD

References

• GOLDGlobal strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease Available from: http://www.goldcopd.com/Accessed August 12, 2015
   Google Scholar
• WHOChronic Obstructive Pulmonary Disease Available from: http://www.who.int/mediacentre/factsheets/fs315/en/Accessed November, 2015
   Google Scholar
• BarrRGBourbeauJCamargoCARamFSInhaled tiotropium for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20052CD00287615846642
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest2014145598199124385182
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res2014157825015176
   PubMed Web of Science ®Google Scholar
• FarneHACatesCJLong-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201510CD008989
   Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• LahousseLVerhammeKMStrickerBHBrusselleGGCardiac effects of current treatments of chronic obstructive pulmonary diseaseLancet Respir Med20164214916426794033
   PubMed Web of Science ®Google Scholar
• GershonACroxfordRCalzavaraACardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary diseaseJAMA Intern Med2013173131175118523689820
   PubMed Web of Science ®Google Scholar
• SalpeterSROrmistonTMSalpeterEECardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysisChest200412562309232115189956
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKEnrightPFurbergCDPro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medicationsThorax201368111411622764216
   PubMed Web of Science ®Google Scholar
• ChenWThomasJSadatsafaviMFitzGeraldJMRisk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisLancet Respir Med20153863163926208998
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med201414424438744
   PubMed Web of Science ®Google Scholar
• FukuchiYSamoroRFassakhovRBudesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study resultsRespirology201318586687323551359
   PubMed Web of Science ®Google Scholar
• GelbAFTashkinDPMakeBJZhongXGarcia GilECaractaCLAS-MD-35 study investigatorsLong-term safety and efficacy of twice-daily aclidinium bromide in patients with COPDRespir Med2013107121957196523916502
   PubMed Web of Science ®Google Scholar
• Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patientsCOPD20107641842721166630
   PubMedGoogle Scholar
• HuCJiaJDongKPharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trialPLoS One2015103e012126425816315
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• NaccarelliGFinkleJChopraBBrooksJHarrisSChruchACardiovascular safety of Umeclidinium/Vilanterol in COPD: Results from eight randomized clinical trialsPresented at: San Diego, California: ATS ConferenceMay 16–21, 2014
   Google Scholar
• SilerTMKerwinESousaARDonaldAAliRChurchAEfficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studiesRespir Med201510991155116326117292
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDMunzuCKilbrideSChurchAMagnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trialsRespir Med2016112657426797016
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeselbaumARCaractaCFAUGMENT COPD study investigatorsEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
   PubMed Web of Science ®Google Scholar
• WedzichaJADahlRBuhlRPooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsRespir Med2014108101498150725135743
   PubMed Web of Science ®Google Scholar
• MahlerDAKerwinEAyersTFLIGHT1 and FLIGHT2: Efficacy and safety of QVA149 (Indacaterol/glycopyrrolate) versus its mono-components and placebo in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519291068107926177074
   PubMed Web of Science ®Google Scholar
• BartlettSJBarnesTMcIvorRAIntegrating patients into meaningful real-world researchAnn Am Thorac Soc201411Suppl 2S112S11724559023
   PubMedGoogle Scholar
• RothwellPMExternal validity of randomised controlled trials: “to whom do the results of this trial apply?Lancet20053659453829315639683
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• FreemantleNStrackTReal-world effectiveness of new medicines should be evaluated by appropriately designed clinical trialsJ Clin Epidemiol201063101053105819880285
   PubMed Web of Science ®Google Scholar
• HalpinDMLessons from the major studies in COPD: problems and pitfalls in translating research evidence into practicePrim Care Respir J201019217017920352172
   PubMedGoogle Scholar
• AlbertRK“Lies, damned lies …” and observational studies in comparative effectiveness researchAm J Respir Crit Care Med2013187111173117723725614
   PubMed Web of Science ®Google Scholar
• CarolanBJSutherlandERClinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advancesJ Allergy Clin Immunol20131313627634 quiz 63523360757
   PubMed Web of Science ®Google Scholar
• VanfleterenLESpruitMAGroenenMClusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013187772873523392440
   PubMed Web of Science ®Google Scholar
• HerlandKAkselsenJPSkjonsbergOHBjermerLHow representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?Respir Med2005991111915672843
   PubMed Web of Science ®Google Scholar
• TraversJMarshSWilliamsMExternal validity of randomised controlled trials in asthma: to whom do the results of the trials apply?Thorax200762321922317105779
   PubMed Web of Science ®Google Scholar
• ScichiloneNBasileMBattagliaSBelliaVWhat proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?Respiration2014871111724281343
   PubMed Web of Science ®Google Scholar
• KruisALStallbergBJonesRCPrimary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation studyPLoS One201493e9014524598945
   PubMed Web of Science ®Google Scholar
• TraversJMarshSCaldwellBExternal validity of randomized controlled trials in COPDRespir Med200710161313132017113277
   PubMed Web of Science ®Google Scholar
• SocietyERThe European Lung White Book: Respiratory Health and Disease in Europe2nd edSheffield, UKEuropean Respiratory Society2013
   Google Scholar
• RodrigueCBeauchesneMFSavariaFAdverse events among COPD patients treated with long-acting anticholinergics and beta2-agonists in an outpatient respiratory clinicRespir Med2016113657326896922
   PubMed Web of Science ®Google Scholar
• NewJPBakerlyNDLeatherDWoodcockAObtaining real-world evidence: the Salford Lung StudyThorax201469121152115424603195
   PubMed Web of Science ®Google Scholar
• GarrisonLPJrNeumannPJEricksonPMarshallDMullinsCDUsing real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force reportValue Health200710532633517888097
   PubMed Web of Science ®Google Scholar
• van BovenJFRoman-RodriguezMKocksJWSorianoJBPostmaMJvan der MolenTPredictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocolNPJ Prim Care Respir Med2015251505126247130
   PubMed Web of Science ®Google Scholar
• KardosPVogelmeierCBuhlRCrieeCPWorthHThe prospective non-interventional DACCORD study in the national COPD registry in Germany: design and methodsBMC Pulm Med201515225578330
   PubMed Web of Science ®Google Scholar
• BakerlyNDWoodcockANewJPThe Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary diseaseRespir Res20151610126337978
   PubMed Web of Science ®Google Scholar
• KardosPBuhlRCriéeC-PVogelmeierCMailaenderCWorthHP46 Frequency of COPD exacerbations in the German DACCORD RegistryThorax201570A98A99
   Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• TashkinDPLeimerIMetzdorfNDecramerMCardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trialRespir Res2015166526031308
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJBrookRDThe study to understand mortality and morbidity in COPD (SUMMIT) study protocolEur Respir J20134151017102223018908
   PubMed Web of Science ®Google Scholar
• RayWAEvaluating medication effects outside of clinical trials: new-user designsAm J Epidemiol2003158991592014585769
   PubMed Web of Science ®Google Scholar
• WorthHBuhlRCrieeCPKardosPMailanderCVogelmeierCThe ‘real-life’ COPD patient in Germany: the DACCORD studyRespir Med2016111647126775251
   PubMed Web of Science ®Google Scholar
• JaraMWentworthC3rdLanesSA new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPDBMJ Open201223 pii:e000841
   Web of Science ®Google Scholar